S&P 500 Tries Its Best to Rebound With Best Day In A Year | Wall Street Today
Gilead Sciences in Charts: Sales From HIV, Liver Disease, and Oncology Therapies Advances in Q2
Gilead Sciences Non-GAAP EPS of $2.01 Beats by $0.41, Revenue of $6.95B Beats by $210M
Pyxis Oncology Draws Buy at Stifel on Lead Asset
J&J, Stryker Among Potential Suitors for Nevro: Wolfe
BofA Upgrades Editas to Buy, Cites Reni-cel Progress
104247826 :
104476495 : hi
On Paris : Good morning
affable Blobfish_403 : With the US economy and stock market being so strong, Wall Street is making public opinion what is the purpose of cutting interest rates?
Laine Ford : maybe in my future
View more comments...